Researchers from Duke CIVIC Vaccine Center (DCVC) developed an mRNA-lipid nanoparticle vaccine incorporating hemagglutinin antigens from 20 different influenza subtypes.
We interviewed the Principal Investigators responsible for leading each of the CIVICs Centers as part of a two-part interview series. Previously, we learned about the
CIVICs | Duke CIVICs Clinical Core | Principal Investigator Profile We interviewed the Principal Investigators (PIs) responsible for leading each of the CIVICs Centers as
The National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs) program is addressing critical gaps in the prevention and control of influenza
We interviewed the Principal Investigators responsible for leading each of the CIVICs Centers as part of a two-part interview series. Previously, we learned about the
CIVICs | Duke Vaccine Manufacturing and Toxicology Core | Principal Investigator Profile We interviewed the Principal Investigators (PIs) responsible for leading each of the CIVICs
We interviewed the Principal Investigators responsible for leading each of the CIVICs Centers as part of a two-part interview series. Previously, we learned about the
CIVICs | Principal Investigator Profile | SDMCC We interviewed the Principal Investigators (PIs) responsible for leading each of the CIVICs Centers as part of a
We interviewed the Principal Investigators responsible for leading each of the CIVICs Centers as part of a two-part interview series. Previously, we learned about the
CIVICs | Principal Investigator Profile | SEM CIVIC We interviewed the Principal Investigators (PIs) responsible for leading each of the CIVICs Centers as part of